Renal tolerance of iotrolan 280 —a meta-analysis of 14 double-blind studies

Clauß, W.; Dinger, Jürgen; Meißner, Carl

doi:10.1007/bf02343267

Cited by 20 publications

(9 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study included a total of 17 prospective clinical trials (1,365 patients), but only 2 of these trials were randomized head-to-head comparisons of iodixanol versus LOCM, and the other data came from the placebo arms of 13 trials of preventive strategies for contrast-induced AKI and the LOCM arms of 2 trials comparing LOCM and HOCM. Finally, a meta-analysis of the renal tolerability of another IOCM, iotrolan 280 (not approved for intravascular use), provides further evidence that IOCM are associated with a lower risk of contrast-induced AKI (49). In this analysis of 14 double-blind studies, it was found that iotrolan had less effect on renal function that the LOCM with which it was compared (iopamidol, iohexol, iopromide).…”

Section: Contrast Medium Usementioning

confidence: 93%

Contrast-Induced Acute Kidney Injury

McCullough

2008

Journal of the American College of Cardiology

807

475

View full text Add to dashboard Cite

Cardiac angiography and coronary/vascular interventions depend on iodinated contrast media and consequently pose the risk of contrast-induced acute kidney injury (AKI). This is an important complication that accounts for a significant number of cases of hospital-acquired renal failure, with adverse effects on prognosis and health care costs. The epidemiology and pathogenesis of contrast-induced AKI, baseline renal function measurement, risk assessment, identification of high-risk patients, contrast medium use, and preventive strategies are discussed in this report. An advanced algorithm is suggested for the risk stratification and management of contrast-induced AKI as it relates to patients undergoing cardiovascular procedures. Contrast-induced AKI is likely to remain a significant challenge for cardiologists in the future because the patient population is aging and chronic kidney disease and diabetes are becoming more common.

show abstract

Section: Contrast Medium Usementioning

confidence: 93%

Contrast-Induced Acute Kidney Injury

McCullough

2008

Journal of the American College of Cardiology

807

475

View full text Add to dashboard Cite

show abstract

“…This study included a total of 17 prospective clinical trials (1,365 patients), but only two of these trials were randomized head-to-head comparisons of iodixanol versus LOCM and the other data came from the placebo arms of 13 trials of preventive strategies for contrast-induced AKI and the LOCM arms of 2 trials comparing LOCM and HOCM. Finally, a meta-analysis of the renal tolerability of another IOCM, iotrolan 280 (not approved for intravascular use), provides further evidence that IOCM are associated with a lower-risk contrast-induced AKI [49]. In this analysis of 14 double-blind studies, it was found that iotrolan had less effect on renal function that the LOCM with which it was compared (iopamidol, iohexol, iopromide).…”

Section: Differences In Iodinated Contrastmentioning

confidence: 99%

Radiocontrast-Induced Acute Kidney Injury

McCullough¹

2008

Nephron Physiol

View full text Add to dashboard Cite

Many radiographic studies and procedures use iodinated contrast media and consequently pose the risk of contrast-induced acute kidney injury (AKI). This is an important complication, which accounts for a significant number of cases of hospital-acquired renal failure associated increased hospital length of stay and increased mortality. Sustained reductions in renal blood flow, hypoxic injury, direct cellular toxicity by the contrast media, and superimposed organ injury are all believed to play a role in this form of AKI. Avoidance of dehydration and multimodality prevention measures may reduce rates of this problem in patients at risk. Contrast-induced AKI is likely to remain a significant challenge for specialists in the future since the patient population is aging, chronic kidney disease and diabetes are coming more common, and use of iodinated contrast is growing.

show abstract

“…Two meta-analyses studies examined 18 and 14 studies comparing iso-osmolar to low-osmolar CM. No significant difference was found regarding ARF 61,62 . A prospective, randomized study with 856 low risk individuals who underwent coronary intervention with administration of iodixanol (iso-osmolar CM) or ioxaglate (low-osmolar CM) did not reveal any difference regarding the incidence of CMIN, although the study did show an expressive 45% reduction in important in-hospital adverse events 63 .…”

Section: Contrast Media Osmolaritymentioning

confidence: 70%